The dal-GenE trial
Evaluating the effects of study drug Dalcetrapib on reducing repeat cardiovascular events in a genetically defined population whom have recently had a heart attack.
Study area: Cardiology
Background: Dalcetrapib is an investigational drug that has been tested in several large clinical trials for its effect on reducing cardiovascular risk in those who have had a heart attack. Results to date have demonstrated that treatment with Dalcetrapib may significantly benefit people who have a particular gene (AA) variant.
Aim: To test the effect of Dalcetrapib only in patients with the AA variant to confirm these findings of cardiovascular benefit.
Who can participate:Anyone aged 45 years and over who has had a heart attack within the last 12 weeks. Exclusions apply; please contact us for more information.